About: Daniel Kuritzkes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Daniel Kuritzkes Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

American physician

Attributes	Values
rdf:type	Item
description	연구원 (ko) araştırmacı (tr) wetenschapper (nl) эрдэмтэн (mn) médecin américain (fr) Ameerika Ühendriikide arst (et) American physician (en) medic american (ro) metge estatunidenc (ca) mjek amerikan (sq) médico estadounidense (es) médico estadounidense (gl) רופא אמריקאי (he) طبيب أمريكي (ar) মার্কিন চিকিৎসক (bn) американський лікар (uk)
rdfs:label	Daniel Kuritzkes (en) Daniel Kuritzkes (fr) Daniel R Kuritzkes (nl)
skos:prefLabel	Daniel Kuritzkes (en) Daniel Kuritzkes (fr) Daniel R Kuritzkes (nl)
name	Daniel Kuritzkes (en) Daniel Kuritzkes (fr) Daniel R Kuritzkes (nl)
Scopus author ID	wds:Q88453812-e3175bd2-4cb6-3aba-8de7-59f5f60f02ad
Scopus author ID	7005078007
given name	wds:Q88453812-4849a78e-4733-b18a-a892-11f40ec1fd85 wds:Q88453812-5A0EE18B-4F3E-436E-B3C8-BFE5BCB4C3E8
given name	Daniel Robert
instance of	wds:Q88453812-AA85601D-7823-4A01-BC82-144A5A6FDA4E
instance of	Homo sapiens
Google Knowledge Graph ID	wds:Q88453812-85FE683A-F3DA-4BE1-8671-9828E25C7097
Google Knowledge Graph ID	http://g.co/kg/g/11f018v166
Google Knowledge Graph ID	/g/11f018v166
skos:altLabel	D R Kuritzkes (en) D. R. Kuritzkes (en) DR Kuritzkes (en) Daniel R Kuritzkes (en) Daniel R. Kuritzkes (en) Daniel Robert Kuritzkes (en)
occupation	wds:Q88453812-7DE1C3A7-1072-4289-B9B9-BEB0DF605E94
sex or gender	wds:Q88453812-D998E39D-BA5D-47C8-99F3-1128AC7B3274
ISNI	wds:Q88453812-069fa416-4f67-e27d-c4f7-0e34c4aca6a4
VIAF ID	wds:Q88453812-3c7e3122-4d17-f5d9-d750-4e166c567c08
Library of Congress authority ID	wds:Q88453812-7161d543-4d7b-913a-8adc-f0cad55f9be6
IdRef ID	wds:Q88453812-da85bdf5-4ee8-c292-4f62-f45c93f8a30c
NDL Authority ID	wds:Q88453812-6b50f334-40f4-4632-a08d-04365cd44280
family name	wds:Q88453812-10088194-4540-1bba-7089-98bd95e70cb8
VIAF ID	http://viaf.org/viaf/21808582
Library of Congress authority ID	http://id.loc.gov/authorities/names/no2002034875
IdRef ID	http://www.idref.fr/085767093/id
NDL Authority ID	http://id.ndl.go.jp/auth/ndlna/001219423
occupation	researcher
sex or gender	male
ISNI	0000000045781796
VIAF ID	21808582
Library of Congress authority ID	no2002034875
IdRef ID	085767093
NDL Authority ID	001219423
family name	Kuritzkes
ORCID iD	wds:Q88453812-36F072C0-4D75-4E60-9B83-F67C7904C4C5
ORCID iD	https://orcid.org/0000-0001-6196-5883
ORCID iD	0000-0001-6196-5883
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q88453812 Daniel Kuritzkes
is author of	Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial Update of the drug resistance mutations in HIV-1: Fall 2005. Tropism testing in the clinical management of HIV-1 infection Accuracy of the TRUGENE HIV-1 genotyping kit. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America Emerging nanotechnology approaches for HIV/AIDS treatment and prevention Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL Clinically validated genotype analysis: guiding principles and statistical concerns. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection Update of the drug resistance mutations in HIV-1: December 2009. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance Drug Resistance Mutations in HIV-1 Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics. Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood Micro-a-fluidics ELISA for rapid CD4 cell count at the point-of-care Simple filter microchip for rapid separation of plasma and viruses from whole blood The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption International AIDS Society global scientific strategy: towards an HIV cure 2016. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211 Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study Monitoring HIV treatment in developing countries

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software